Search Results - "McCurdy, Arleigh"

Pomalidomide by Lacy, Martha Q., McCurdy, Arleigh R.

“…This spotlight review focuses on the second-generation immunomodulatory drug pomalidomide, which was recently approved by the US Food and Drug Administration…”
Get full text

The work of managing multiple myeloma and its implications for treatment-related decision making: a qualitative study of patient and caregiver experiences by Pritlove, Cheryl, Jassi, Mobin, Burns, Bridget, McCurdy, Arleigh

“…Abstract Background The evolving nature of multiple myeloma (MM) therapies, including the introduction of novel oral agents, has produced a shift in the…”
Get full text

Venous thromboembolic events in inflammatory bowel diseases: A review of current evidence and guidance on risk in the post-hospitalization setting by Murthy, Sanjay K., Robertson McCurdy, Arleigh B., Carrier, Marc, McCurdy, Jeffrey D.

“…Venous thromboembolism (VTE) is a life-threatening, yet potentially preventable, complication of inflammatory bowel disease (IBD). The incidence of VTE in IBD…”
Get full text

Just the facts: how to diagnose and manage patients with multiple myeloma in the emergency department? by McCurdy, Arleigh, Mian, Hira, Rosenberg, Hans

Get more information

Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis by KOURELIS, Taxiarchis V, KUMAR, Shaji K, DINGLI, David, LUST, John A, YI LIN, KAPOOR, Prashant, RAJKUMAR, S. Vincent, MCCURDY, Arleigh, DISPENZIERI, Angela, GERTZ, Morie A, LACY, Martha Q, BUADI, Francis K, HAYMAN, Suzanne R, ZELDENRUST, Steven, LEUNG, Nelson, KYLE, Robert A, RUSSELL, Stephen

“…There is consensus that patients with light chain (AL) amyloidosis with hypercalcemia, renal failure, anemia, and lytic bone lesions attributable to clonal…”
Get full text

External validation of the FIRST trial’s simplified frailty score in a population-based cohort by Mian, Hira S., Giri, Smith, Wildes, Tanya M., Balitsky, Amaris K., McCurdy, Arleigh, Pond, Gregory R., Sivapathasundaram, Branavan, Seow, Hsien

Get full text

Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study by McCurdy, Arleigh, Seow, Hsien, Pond, Gregory P, Gayowsky, Anastasia, Chakraborty, Rajshekhar, Visram, Alissa, Kaedbey, Rayan, D'Souza, Anita, Mohyuddin, Ghulam Rehman, Wildes, Tanya M, Fonseca, Rafael, Mian, Hira

“…Survival has improved in patients diagnosed with multiple myeloma (MM) over the last two decades; however, there remains a paucity of data on the causes of…”
Get full text

Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma by KAPOOR, Prashant, KUMAR, Shaji K, LEUNG, Nelson, YI LIN, ZELDENRUST, Steven R, MCCURDY, Arleigh, GREIPP, Philip R, KYLE, Robert A, RAJKUMAR, S. Vincent, GERTZ, Morie A, DISPENZIERI, Angela, LACY, Martha Q, BUADI, Francis, DINGLI, David, RUSSELL, Stephen J, HAYMAN, Suzanne R, WITZIG, Thomas E, LUST, John A

“…To study the impact of achieving stringent complete response (sCR), an increasingly attainable goal, after autologous stem-cell transplantation (ASCT) in…”
Get full text

Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study by Visram, Alissa, Chan, Kelvin Kar-Wing, Seow, Hsien, Pond, Gregory, Gayowsky, Anastasia, Mohyuddin, Ghulam Rehman, McCurdy, Arleigh, Sandhu, Irwindeep, Venner, Christopher, Lancman, Guido, Balitsky, Amaris, Kouroukis, Tom, Bruins, Robert, Kumar, Shaji, Fonseca, Rafael, Mian, Hira

“…Not available.Not available…”
Get full text

The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review by Mian, Hira, McCurdy, Arleigh, Giri, Smith, Grant, Shakira, Rochwerg, Bram, Winks, Erica, Rosko, Ashley E., Engelhardt, Monika, Pawlyn, Charlotte, Cook, Gordon, Jackson, Graham, Bringhen, Sara, Facon, Thierry, Larocca, Alessandra, Zweegman, Sonja, Wildes, Tanya M.

“…Multiple myeloma (MM) is an incurable blood cancer that primarily affects older adults. Several frailty tools have been developed to address the heterogeneity…”
Get full text

The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database by Cherniawsky, Hannah M., Kukreti, Vishal, Reece, Donna, Masih-Khan, Esther, McCurdy, Arleigh, Jimenez-Zepeda, Victor H., Sebag, Michael, Song, Kevin, White, Darrell, Stakiw, Julie, LeBlanc, Richard, Reiman, Anthony, Aslam, Muhammad, Louzada, Martha, Kotb, Rami, Gul, Engin, Atenafu, Eshetu, Venner, Christopher P.

Get full text

Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial by McCurdy, Arleigh, Reece, Donna, Louzada, Martha L., White, Darrell, Parkin, Stephen, Chu, Michael P., Kotb, Rami, Mian, Hira, Othman, Ibraheem, Su, Jiandong, Khan, Aniba, Gul, Engin, Trudel, Suzanne

“…Given the early use of triplet and quadruplet regimens, most patients with multiple myeloma (MM) will be exposed and/or refractory to PIs, IMiDs, and anti-CD38…”
Get full text

When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer by Hasim, Mohamed S, Marotel, Marie, Hodgins, Jonathan J, Vulpis, Elisabetta, Makinson, Olivia J, Asif, Sara, Shih, Han-Yu, Scheer, Amit K, MacMillan, Olivia, Alonso, Felipe G, Burke, Kelly P, Cook, David P, Li, Rui, Petrucci, Maria Teresa, Santoni, Angela, Fallon, Padraic G, Sharpe, Arlene H, Sciumè, Giuseppe, Veillette, André, Zingoni, Alessandra, Gray, Douglas A, McCurdy, Arleigh, Ardolino, Michele

“…Trogocytosis modulates immune responses, with still unclear underlying molecular mechanisms. Using leukemia mouse models, we found that lymphocytes perform…”
Get full text

Decision-making factors for an autologous stem cell transplant for older adults with newly diagnosed multiple myeloma: A qualitative analysis by Mian, Owais, Puts, Martine, McCurdy, Arleigh, Wildes, Tanya M, Fiala, Mark A, Kang, Matthew, Salib, Mary, Alibhai, Shabbir, Mian, Hira

“…A utologous stem cell transplant (ASCT) remains a standard of care among older adults (aged ≥65) with multiple myeloma (MM). However, heterogeneity in the…”
Get full text

Smoldering multiple myeloma requiring treatment: time for a new definition? by Dispenzieri, Angela, Stewart, A. Keith, Chanan-Khan, Asher, Rajkumar, S. Vincent, Kyle, Robert A., Fonseca, Rafael, Kapoor, Prashant, Bergsagel, P. Leif, McCurdy, Arleigh, Gertz, Morie A., Lacy, Martha Q., Lust, John A., Russell, Stephen J., Zeldenrust, Steven R., Reeder, Craig, Roy, Vivek, Buadi, Francis, Dingli, David, Hayman, Suzanne R., Leung, Nelson, Lin, Yi, Mikhael, Joseph, Kumar, Shaji K.

“…Smoldering multiple myeloma (SMM) bridges the gap between monoclonal gammopathy of undetermined significance (a mostly premalignant disorder) and active…”
Get full text

Anaplastic large cell lymphoma as a posttransplant lymphoproliferative disorder in a renal transplant patient: A case report by Alabdulbaqi, Manar, Toupin, Melissa, Berardi, Philip, McCurdy, Arleigh

“…We report a case of a 45‐year‐old female who developed an ALK‐positive anaplastic large cell lymphoma (ALCL) 9 years after renal transplant. The patient…”
Get full text

Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis by McCurdy, Arleigh, Mian, Hira, LeBlanc, Richard, Jimenez-Zepeda, Victor H., Su, Jiandong, Masih-Khan, Esther, Visram, Alissa, Louzada, Martha, Song, Kevin, White, Darrell, Sebag, Michael, Stakiw, Julie, Reiman, Anthony, Aslam, Muhammad, Bergstrom, Debra, Kotb, Rami, Kaedbey, Rayan, Gul, Engin, Reece, Donna, Venner, Christopher P.

“…While most patients diagnosed with multiple myeloma (MM) receive initial therapy, reported attrition rates are high. Understanding attrition rates and…”
Get full text

Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database by Côté, Julie, LeBlanc, Richard, Mian, Hira, Chu, Michael P., McCurdy, Arleigh, Masih-Khan, Esther, Su, Jiandong, Jimenez-Zepeda, Victor H., Song, Kevin, Louzada, Martha, White, Darrell, Sebag, Michael, Reiman, Anthony, Stakiw, Julie, Kotb, Rami, Bergstrom, Debra, Aslam, Muhammad, Kaedbey, Rayan, Venner, Christopher P., Gul, Engin, Reece, Donna

“…Autologous stem cell transplant (ASCT) remains an important option for eligible multiple myeloma (MM) patients as part of initial therapy. Using the Canadian…”
Get full text

Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study by Tanguay, Mégane, Roy, Jean, Su, Jiandong, Gul, Engin, Reece, Donna, Venner, Christopher P., White, Darrell, Chu, Michael P., Jimenez‐Zepada, Victor H., Song, Kevin, Mccurdy, Arleigh, Mian, Hira, Sebag, Michael, Bergstrom, Debra, Stakiw, Julie, Reiman, Anthony, Kotb, Rami, Aslam, Muhammad, Kaedbey, Rayan, Louzada, Martha, LeBlanc, Richard

“…ABSTRACT Background Young patients ≤ 50 years old with multiple myeloma (MM) account for about 10% of cases and are underrepresented in the literature. Methods…”
Get full text

Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales by Tay, Jason, Vij, Ravi, Norkin, Maxim, Buadi, Francis, Kindwall-Keller, Tamila L., Roberts, Jenna S., White, Darrell J., Wood, Robert P., Blanthorn-Hazell, Sophee E., Rossi, Adriana C., Dhanasiri, Sujith, Zafar, Faiza, Newhouse, Kim, McCurdy, Arleigh R.

“…Maintenance (MT) may be prescribed after autologous stem cell transplant (ASCT) but there are often concerns about the impact on quality of life (QoL). QoL was…”
Get full text